Developing Next-Generation Anti-Androgen Therapies for CRPC

March 21, 2014
Robert Dreicer, MD, MS

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer

Robert Dreicer, MD, MS, professor of medicine at the Cleveland Clinic Lerner College of Medicine, chairman, Department of Solid Tumor Oncology, Taussig Cancer Institute, discusses next-generation anti-androgen therapies for patients with castration-resistant prostate cancer (CRPC).

Clinical Pearls:

  • Developing next-generation androgen receptor (AR) therapies is challenging because many have similar activity to drugs that are already approved
  • Orteronel, an androgen synthesis inhibitor, was unable to meet its primary endpoint of improvement in overall survival compared with placebo in a phase III trial
  • In order to gain approval, new AR-targeted drugs must be dramatically better than the drugs that are already available